

Ellen McPhail

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/918055/publications.pdf>

Version: 2024-02-01

128
papers

6,144
citations

57631

44
h-index

71532

76
g-index

130
all docs

130
docs citations

130
times ranked

5814
citing authors

#	ARTICLE	IF	CITATIONS
1	A mutation in the SAA1 promoter causes hereditary amyloid A amyloidosis. <i>Kidney International</i> , 2022, 101, 349-359.	2.6	10
2	The characteristics of patients with kidney light chain deposition disease concurrent with light chain amyloidosis. <i>Kidney International</i> , 2022, 101, 152-163.	2.6	6
3	Unraveling a rare cause of spinal stenosis: Coexistent AL and ATTR amyloidosis involving the ligamentum flavum. , 2022, 13, 12.		2
4	Immunohistochemistry for LEF1 and SOX11 adds diagnostic specificity in small B-cell lymphomas. <i>Human Pathology</i> , 2022, 121, 29-35.	1.1	5
5	Bone marrow amyloid: a comprehensive analysis of 1,469 samples, including amyloid type, clinical features, and morphologic distribution. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2022, 29, 156-164.	1.4	5
6	The Relationship Between Wild-Type Transthyretin Amyloid Load and Ligamentum Flavum Thickness in Lumbar Stenosis Patients. <i>World Neurosurgery</i> , 2022, 164, e113-e118.	0.7	4
7	Machine Learning Quantification of Amyloid Deposits in Histological Images of Ligamentum Flavum. <i>Journal of Pathology Informatics</i> , 2022, 13, 100013.	0.8	5
8	Aberrant expression of lymphoid enhancerâ€“binding factor 1 in Hodgkin lymphoma. <i>Human Pathology</i> , 2022, 125, 2-10.	1.1	2
9	A novel substitution of proline (P32L) destabilises Î²2-microglobulin inducing hereditary systemic amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2022, , 1-8.	1.4	2
10	Sclerosing extramedullary hematopoietic tumor in chronic myeloproliferative neoplasms. <i>Blood</i> , 2022, 139, 3345-3345.	0.6	1
11	Lumbar stenosis due to wild-type transthyretin amyloidâ€“induced thickening of the ligamentum flavum: a separate etiology from degeneration of intervertebral discs?. <i>Journal of Neurosurgery: Spine</i> , 2022, 37, 687-693.	0.9	1
12	The novel form of amyloidosis derived from EGFâ€“containing fibulinâ€“like extracellular matrix protein 1 (EFEMP1) preferentially affects the lower gastrointestinal tract of elderly females^a. <i>Histopathology</i> , 2021, 78, 459-463.	1.6	7
13	Nonâ€“cardiac biopsy sites with high frequency of transthyretin amyloidosis. <i>ESC Heart Failure</i> , 2021, 8, 750-755.	1.4	7
14	Amyloid arthropathy in smoldering myeloma: Do not take it lightly. <i>Leukemia Research Reports</i> , 2021, 15, 100242.	0.2	2
15	Immunoglobulin-Negative DNAJB9-Associated Fibrillary Glomerulonephritis: A Report of 9 Cases. <i>American Journal of Kidney Diseases</i> , 2021, 77, 454-458.	2.1	10
16	JAK2 activation promotes tumorigenesis in ALK-negative anaplastic large cell lymphoma via regulating oncogenic STAT1-PVT1 lncRNA axis. <i>Blood Cancer Journal</i> , 2021, 11, 56.	2.8	3
17	IGVL gene region usage correlates with distinct clinical presentation in IgM vs non-IgM light chain amyloidosis. <i>Blood Advances</i> , 2021, 5, 2101-2105.	2.5	7
18	Paraneoplastic REG1Î± Cast Nephropathyâ€“Associated With Mixed Acinar-Neuroendocrine Carcinoma. <i>Kidney International Reports</i> , 2021, 6, 1178-1182.	0.4	1

#	ARTICLE	IF	CITATIONS
19	The Clinical Impact of Proteomics in Amyloid Typing. Mayo Clinic Proceedings, 2021, 96, 1122-1127.	1.4	9
20	Donor-Derived ALECT2 Amyloidosis and Recurrent Fibrillary Glomerulonephritis in a Transplant Allograft. Kidney Medicine, 2021, 3, 433-437.	1.0	2
21	Treatment of AL Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement 2020 Update. Mayo Clinic Proceedings, 2021, 96, 1546-1577.	1.4	32
22	Association between spinal stenosis and wild-type ATTR amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2021, 28, 226-233.	1.4	23
23	Somatostatin-derived amyloidosis: a novel type of amyloidosis associated with well-differentiated somatostatin-producing neuroendocrine tumours. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2021, , 1-6.	1.4	2
24	Amyloid light-chain deposition in a schwannoma. Interdisciplinary Neurosurgery: Advanced Techniques and Case Management, 2021, 26, 101301.	0.2	0
25	Striking Association of Lymphoid Enhancing Factor (LEF1) Overexpression and DUSP22 Rearrangements in Anaplastic Large Cell Lymphoma. American Journal of Surgical Pathology, 2021, 45, 550-557.	2.1	20
26	MYC break-apart FISH probe set reveals frequent unbalanced patterns of uncertain significance when evaluating aggressive B-cell lymphoma. Blood Cancer Journal, 2021, 11, 184.	2.8	6
27	First Report of Bilateral External Auditory Canal Cochlin Aggregates (â€œCochlinomasâ€) with Multifocal Amyloid-Like Deposits, Associated with Sensorineural Hearing Loss and a Novel Genetic Variant in COCH Encoding Cochlin. Head and Neck Pathology, 2020, 14, 808-816.	1.3	2
28	Light chain only variant of proliferative glomerulonephritis with monoclonal immunoglobulin deposits is associated with a high detection rate of the pathogenic plasma cell clone. Kidney International, 2020, 97, 589-601.	2.6	32
29	Transthyretin amyloidosis: Putting myopathy on the map. Muscle and Nerve, 2020, 61, 95-100.	1.0	27
30	IgM AL amyloidosis: delineating disease biology and outcomes with clinical, genomic and bone marrow morphological features. Leukemia, 2020, 34, 1373-1382.	3.3	40
31	A Proteomic Atlas of Cardiac Amyloid Plaques. JACC: CardioOncology, 2020, 2, 632-643.	1.7	20
32	Amyloid Typing by Mass Spectrometry in Clinical Practice: a Comprehensive Review of 16,175 Samples. Mayo Clinic Proceedings, 2020, 95, 1852-1864.	1.4	105
33	Incidental Richter transformation in chronic lymphocytic leukemia patients during temporary interruption of ibrutinib. Blood Advances, 2020, 4, 4508-4511.	2.5	15
34	A practical approach to FISH testing for MYC rearrangements and brief review of MYC in aggressive B-cell lymphomas. Journal of Hematopathology, 2020, 13, 127-135.	0.2	2
35	High level MYC amplification in B-cell lymphomas: is it a marker of aggressive disease?. Blood Cancer Journal, 2020, 10, 5.	2.8	22
36	Striking Association of Lymphoid Enhancing Factor (LEF1) Overexpression and <i>DUSP22</i> rearrangements in Anaplastic Large Cell Lymphoma. Blood, 2020, 136, 22-23.	0.6	0

#	ARTICLE	IF	CITATIONS
37	Two types of amyloidosis presenting in a single patient: a case series. <i>Blood Cancer Journal</i> , 2019, 9, 30.	2.8	48
38	Heavy Chain Fibrillary Glomerulonephritis: A Case Report. <i>American Journal of Kidney Diseases</i> , 2019, 74, 276-280.	2.1	16
39	Monoclonal gammopathy plus positive amyloid biopsy does not always equal AL amyloidosis. <i>American Journal of Hematology</i> , 2019, 94, E141-E143.	2.0	17
40	Fatal TTR amyloidosis with neuropathy from domino liver p.Val71Ala transplant. <i>Neurology: Genetics</i> , 2019, 5, e351.	0.9	4
41	False-negative rates for <i>MYC</i> fluorescence <i>in situ</i> hybridization probes in B-cell neoplasms. <i>Haematologica</i> , 2019, 104, e248-e251.	1.7	43
42	A Proteomic Atlas of Cardiac Amyloidosis. <i>Blood</i> , 2019, 134, 1790-1790.	0.6	1
43	Integration of Genetic, Transcriptomic, and Immune Profiles Reveals Genomically-Distinct Populations in Low-Grade Lymphomas. <i>Blood</i> , 2019, 134, 2764-2764.	0.6	0
44	Immunoglobulin Variable Gene Region (IGVL) Usage Correlates with Distinct Clinical Presentation in IgM Versus Non-IgM Light Chain Amyloidosis. <i>Blood</i> , 2019, 134, 1770-1770.	0.6	0
45	Fifty-Year Incidence of Waldenström Macroglobulinemia in Olmsted County, Minnesota, From 1961 Through 2010: A Population-Based Study With Complete Case Capture and Hematopathologic Review. <i>Mayo Clinic Proceedings</i> , 2018, 93, 739-746.	1.4	29
46	<i>MYD88</i> mutation status does not impact overall survival in Waldenström macroglobulinemia. <i>American Journal of Hematology</i> , 2018, 93, 187-194.	2.0	57
47	<i>DNAJB9</i> Is a Specific Immunohistochemical Marker for Fibrillary Glomerulonephritis. <i>Kidney International Reports</i> , 2018, 3, 56-64.	0.4	109
48	Immunophenotypic and laboratory features of t(11;14)(q13;q32)-positive plasma cell neoplasms. <i>Leukemia and Lymphoma</i> , 2018, 59, 1913-1919.	0.6	2
49	Prognostic and therapeutic significance of phosphorylated STAT3 and protein tyrosine phosphatase-6 in peripheral-T cell lymphoma. <i>Blood Cancer Journal</i> , 2018, 8, 110.	2.8	22
50	Defining Lymphoplasmacytic Lymphoma. <i>American Journal of Clinical Pathology</i> , 2018, 150, 168-176.	0.4	5
51	Apolipoprotein CII Amyloidosis Associated With p.Lys41Thr Mutation. <i>Kidney International Reports</i> , 2018, 3, 1193-1201.	0.4	21
52	Inferior survival in high-grade B-cell lymphoma with <i>MYC</i> and <i>BCL2</i> and/or <i>BCL6</i> rearrangements is not associated with <i>MYC/IG</i> gene rearrangements. <i>Haematologica</i> , 2018, 103, 1899-1907.	1.7	52
53	Genetic subtyping of breast implant-associated anaplastic large cell lymphoma. <i>Blood</i> , 2018, 132, 544-547.	0.6	99
54	High Level MYC Amplification in Aggressive B-Cell Lymphomas: Is It a Marker of Aggressive Disease?. <i>Blood</i> , 2018, 132, 1693-1693.	0.6	1

#	ARTICLE	IF	CITATIONS
55	Plasma Cell Disorders in Patients with Age-Related Transthyretin (ATTRwt) Amyloidosis. <i>Blood</i> , 2018, 132, 5610-5610.	0.6	0
56	Morphologic Features of ALK-negative Anaplastic Large Cell Lymphomas With DUSP22 Rearrangements. <i>American Journal of Surgical Pathology</i> , 2016, 40, 36-43.	2.1	103
57	Everolimus combined with R-CHOP-21 for new, untreated, diffuse large B-cell lymphoma (NCCTG 1085) Tj ETQq1 1 0.784314 rgBT / O e309-e316.	2.2	50
58	LMO2 Is a Specific Marker of T-Lymphoblastic Leukemia/Lymphoma. <i>American Journal of Clinical Pathology</i> , 2016, 145, 180-190.	0.4	23
59	Treatment and Clinical Outcomes of High Grade B-Cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements (Double Hit/Triple Hit Lymphomas). <i>Blood</i> , 2016, 128, 155-155.	0.6	1
60	Prognostic Impact of Morphology, MYC Gene Partner and BCL2/BCL6 Translocation Status in "High Grade B-Cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements". <i>Blood</i> , 2016, 128, 1750-1750.	0.6	2
61	Lymph Node. , 2016, , 751-789.		0
62	High-grade B-cell Lymphoma Mimicking an Unresectable Pancreatic Carcinoma. <i>American Journal of Gastroenterology</i> , 2016, 111, S519.	0.2	0
63	Genome-Wide Analysis Uncovers Novel Recurrent Alterations in Primary Central Nervous System Lymphomas. <i>Clinical Cancer Research</i> , 2015, 21, 3986-3994.	3.2	172
64	Immunophenotypic features by multiparameter flow cytometry can help distinguish low grade B-cell lymphomas with plasmacytic differentiation from plasma cell proliferative disorders with an unrelated clonal B-cell process. <i>British Journal of Haematology</i> , 2015, 169, 368-376.	1.2	23
65	Synovial Infiltration in Human T Lymphotropic Virus Type 1-Associated Adult T Cell Leukemia/Lymphoma. <i>Arthritis and Rheumatology</i> , 2015, 67, 945-945.	2.9	2
66	Analysis of Amyloid in Medullary Thyroid Carcinoma by Mass Spectrometry-Based Proteomic Analysis. <i>Endocrine Pathology</i> , 2015, 26, 291-295.	5.2	25
67	Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue of the Salivary Glands: A Multicenter, International Experience of 248 Patients (IELSG 41). <i>Oncologist</i> , 2015, 20, 1149-1153.	1.9	52
68	Whole-exome analysis reveals novel somatic genomic alterations associated with outcome in immunochemotherapy-treated diffuse large B-cell lymphoma. <i>Blood Cancer Journal</i> , 2015, 5, e346-e346.	2.8	54
69	Everolimus Plus RCHOP-21 Is Safe and Highly Effective for New Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results of the Phase I Trial NCCTG1085 (Alliance). <i>Blood</i> , 2015, 126, 813-813.	0.6	1
70	Lymphocyte-to-Monocyte Ratio at Diagnosis and Survival in De Novo Double/Triple Hit Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2015, 126, 3885-3885.	0.6	0
71	A prospective, randomized crossover study comparing direct inspection by light microscopy versus projected images for teaching of hematopathology to medical students. <i>Anatomical Sciences Education</i> , 2014, 7, 130-134.	2.5	8
72	Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT) of the Salivary Gland Is Associated with Improved Prognosis When Arising in a Background of Sjögren's Disease and May Not Benefit from Local Therapy. <i>Blood</i> , 2014, 124, 1637-1637.	0.6	7

#	ARTICLE	IF	CITATIONS
73	Clonally Related Follicular Lymphomas and Langerhans Cell Neoplasms. American Journal of Surgical Pathology, 2013, 37, 978-986.	2.1	69
74	The Genomic Landscape Of Primary Central Nervous System Lymphomas. Blood, 2013, 122, 504-504.	0.6	1
75	Detection of human papilloma virus and p16 expression in high-grade adenoid cystic carcinoma of the head and neck. Modern Pathology, 2012, 25, 529-536.	2.9	74
76	Expression of <i>MALT1</i> oncogene in hematopoietic stem/progenitor cells recapitulates the pathogenesis of human lymphoma in mice. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 10534-10539.	3.3	73
77	t(X;14)(p11;q32) in MALT lymphoma involving GPR34 reveals a role for GPR34 in tumor cell growth. Blood, 2012, 120, 3949-3957.	0.6	48
78	Genome-Wide Analysis Uncovers Recurrent Alterations in Primary Central Nervous System Lymphomas. Blood, 2012, 120, 420-420.	0.6	1
79	An Integrated Genomic and Expression Analysis of 7q Deletion in Splenic Marginal Zone Lymphoma. PLoS ONE, 2012, 7, e44997.	1.1	53
80	Abstract 4507: Deletion of 9p21.3/p16/CDKN2A is associated with poorer survival in primary central nervous system (PCNSL) lymphoma independent of 6q22 effect. A study facilitated by the Surveillance, Epidemiology and End Results Tissue Repository Program (SEER TRP). , 2012, , .		0
81	Abstract 5081: Comprehensive genomic analysis of primary CNS lymphomas (PCNSL) identifies multiple dysregulated genes involved in immune response, regulation of apoptosis, lymphocyte maturation and activation. , 2012, , .		0
82	BCL-6 expression in mesenchymal tumours: an immunohistochemical and fluorescence in situ hybridisation study. Journal of Clinical Pathology, 2011, 64, 866-869.	1.0	6
83	Influence of 6q22 on overall survival in primary central nervous system lymphoma. Analysis of North Central Cancer Treatment Group trials 86 72 52, 93 73 51 and 96 73 51. British Journal of Haematology, 2011, 154, 146-150.	1.2	3
84	Relapsed hepatosplenic T-cell lymphoma heralded by a solitary skin nodule. Journal of Cutaneous Pathology, 2011, 38, 899-904.	0.7	7
85	Primary Central Nervous System Lymphomas: A Validation Study of Array-Based Comparative Genomic Hybridization in Formalin-Fixed Paraffin-Embedded Tumor Specimens. Clinical Cancer Research, 2011, 17, 4245-4253.	3.2	52
86	Primary Parotid MALT Lymphoma: Clinical Characteristics and Treatment at a Single Institution Experience. Blood, 2011, 118, 1580-1580.	0.6	1
87	Dysregulation of GPR34 in Indolent Lymphomas and Its Function As a Novel Regulator of Cell Growth and Gene Expression. Blood, 2011, 118, 1570-1570.	0.6	15
88	CD5+ B-cell lymphoproliferative disorders: Beyond chronic lymphocytic leukemia and mantle cell lymphoma. Leukemia Research, 2010, 34, 1235-1238.	0.4	30
89	Splenic marginal zone lymphoma: characterization of 7q deletion and its value in diagnosis. Journal of Pathology, 2010, 220, 461-474.	2.1	61
90	Coexisting Follicular and Mantle Cell Lymphoma With Each Having an In Situ Component. American Journal of Clinical Pathology, 2010, 133, 584-591.	0.4	58

#	ARTICLE	IF	CITATIONS
91	Expression of LMO2 Is Associated With t(14;18)/IGH-BCL2 Fusion but Not BCL6 Translocations in Diffuse Large B-Cell Lymphoma. <i>American Journal of Clinical Pathology</i> , 2010, 134, 278-281.	0.4	8
92	Defining the borders of splenic marginal zone lymphoma: a multiparameter study. <i>Human Pathology</i> , 2010, 41, 540-551.	1.1	33
93	Primary Pulmonary MALT Lymphoma: Clinical Characteristics and Treatment Outcomes – Single Institution Experience. <i>Blood</i> , 2010, 116, 4168-4168.	0.6	5
94	Cyclin D1 positive follicular lymphoma. <i>Journal of Clinical Pathology</i> , 2009, 62, 855-857.	1.0	5
95	Recurrent translocations involving the IRF4 oncogene locus in peripheral T-cell lymphomas. <i>Leukemia</i> , 2009, 23, 574-580.	3.3	195
96	Novel immunophenotypic features of marrow lymphoplasmacytic lymphoma and correlation with Waldenström's macroglobulinemia. <i>Modern Pathology</i> , 2009, 22, 807-816.	2.9	159
97	Sclerosing extramedullary hematopoietic tumor: emphasis on diagnosis by renal biopsy. <i>Annals of Diagnostic Pathology</i> , 2009, 13, 127-131.	0.6	20
98	Gene expression profiling of pulmonary mucosa-associated lymphoid tissue lymphoma identifies new biologic insights with potential diagnostic and therapeutic applications. <i>Blood</i> , 2009, 113, 635-645.	0.6	52
99	Overexpression of Syk tyrosine kinase in peripheral T-cell lymphomas. <i>Leukemia</i> , 2008, 22, 1139-1143.	3.3	136
100	The prevalence of IG translocations and 7q32 deletions in splenic marginal zone lymphoma. <i>Leukemia</i> , 2008, 22, 1268-1272.	3.3	40
101	Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria. <i>Leukemia</i> , 2008, 22, 487-495.	3.3	244
102	Predictive Value of Blood and Bone Marrow Flow Cytometry in B-Cell Lymphoma Classification: Comparative Analysis of Flow Cytometry and Tissue Biopsy in 252 Patients. <i>Mayo Clinic Proceedings</i> , 2008, 83, 776-785.	1.4	90
103	Del(6)(q22) and <i>BCL6</i> Rearrangements in Primary CNS Lymphoma Are Indicators of an Aggressive Clinical Course. <i>Journal of Clinical Oncology</i> , 2008, 26, 4814-4819.	0.8	109
104	Incidence of TCR and TCL1 Gene Translocations and Isochromosome 7q in Peripheral T-Cell Lymphomas Using Fluorescence In Situ Hybridization. <i>American Journal of Clinical Pathology</i> , 2008, 130, 178-185.	0.4	45
105	The centrosome index is a powerful prognostic marker in myeloma and identifies a cohort of patients that might benefit from aurora kinase inhibition. <i>Blood</i> , 2008, 111, 1603-1609.	0.6	111
106	Chromosomal translocations involving BCL6 in MALT lymphoma. <i>Haematologica</i> , 2008, 93, 145-146.	1.7	25
107	Clinical Course and Prognosis of Smoldering (Asymptomatic) Multiple Myeloma. <i>New England Journal of Medicine</i> , 2007, 356, 2582-2590.	13.9	740
108	The International Prognostic Index predicts outcome after histological transformation of low-grade non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2006, 47, 1794-1799.	0.6	8

#	ARTICLE	IF	CITATIONS
109	Splenic small B-cell lymphoma with IGH/BCL3 translocation. <i>Human Pathology</i> , 2006, 37, 218-230.	1.1	28
110	The Incidence and Anatomic Site Specificity of Chromosomal Translocations in Primary Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue (MALT Lymphoma) in North America. <i>American Journal of Surgical Pathology</i> , 2006, 30, 1546-1553.	2.1	203
111	Expression of CXCL13, a chemokine highly upregulated in germinal center T-helper cells, distinguishes angioimmunoblastic T-cell lymphoma from peripheral T-cell lymphoma, unspecified. <i>Modern Pathology</i> , 2006, 19, 1101-1107.	2.9	133
112	Novel FISH probes designed to detect IGH-MYC and IGL-MYC rearrangements in B-cell lineage malignancy identify a new breakpoint cluster region designated BVR2. <i>Leukemia</i> , 2006, 20, 1790-1799.	3.3	43
113	Strong BCL10 nuclear expression identifies gastric MALT lymphomas that do not respond to H pylori eradication. <i>Gut</i> , 2006, 55, 137-138.	6.1	61
114	Angioimmunoblastic T-cell lymphoma: a neoplasm of germinal-center T-helper cells?. <i>Blood</i> , 2005, 106, 1501-1502.	0.6	161
115	Interphase fluorescence in situ hybridization with an IGH probe is important in the evaluation of patients with a clinical diagnosis of chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2005, 130, 36-42.	1.2	56
116	MALT lymphoma with t(14;18)(q32;q21)/IGH-MALT1 is characterized by strong cytoplasmic MALT1 and BCL10 expression. <i>Journal of Pathology</i> , 2005, 205, 293-301.	2.1	149
117	Primary pulmonary MALT lymphomas show frequent and heterogeneous cytogenetic abnormalities, including aneuploidy and translocations involving API2 and MALT1 and IGH and MALT1. <i>Leukemia</i> , 2004, 18, 156-160.	3.3	78
118	Inhibition of survivin expression suppresses the growth of aggressive non-Hodgkin's lymphoma. <i>Leukemia</i> , 2004, 18, 616-623.	3.3	83
119	Despite apparent morphologic and immunophenotypic heterogeneity, Waldenstrom's macroglobulinemia is consistently composed of cells along a morphologic continuum of small lymphocytes, plasmacytoid lymphocytes, and plasma cells. <i>Seminars in Oncology</i> , 2003, 30, 182-186.	0.8	70
120	Long-term follow-up of IgM monoclonal gammopathy of undetermined significance. <i>Blood</i> , 2003, 102, 3759-3764.	0.6	279
121	A New Method to Extract Nuclei from Paraffin-Embedded Tissue to Study Lymphomas Using Interphase Fluorescence in Situ Hybridization. <i>American Journal of Pathology</i> , 2002, 160, 1967-1972.	1.9	100
122	Mucosa-Associated Lymphoid Tissue Lymphomas with t(11;18)(q21;q21) and Mucosa-Associated Lymphoid Tissue Lymphomas with Aneuploidy Develop Along Different Pathogenetic Pathways. <i>American Journal of Pathology</i> , 2002, 161, 63-71.	1.9	107
123	Pelvic Castleman disease presenting as vaginal occlusion. <i>Obstetrics and Gynecology</i> , 2002, 100, 1082-1085.	1.2	6
124	Sclerosing Extramedullary Hematopoietic Tumor in Chronic Myeloproliferative Disorders. <i>American Journal of Surgical Pathology</i> , 2000, 24, 51.	2.1	53
125	Diagnostic utility of fluorescence in situ hybridization in mantle-cell lymphoma. <i>British Journal of Haematology</i> , 2000, 110, 856-862.	1.2	109
126	Incidence and Subtype Specificity of API2-MALT1 Fusion Translocations in Extranodal, Nodal, and Splenic Marginal Zone Lymphomas. <i>American Journal of Pathology</i> , 2000, 156, 1183-1188.	1.9	210

#	ARTICLE	IF	CITATIONS
127	Multiple Cerebral Infarctions From Nonbacterial Thrombotic Endocarditis Mimicking Cerebral Vasculitis. Mayo Clinic Proceedings, 1999, 74, 798-802.	1.4	19
128	Plexiform Fibrohistiocytic Tumor: Clinicopathologic Analysis of 22 Cases. American Journal of Surgical Pathology, 1999, 23, 662-670.	2.1	129